Datapoint: Ascendis Scores Approval for First Once-Weekly Childhood GHD Drug
September 2
The FDA last week cleared Ascendis Pharma’s Skytrofa, a long-acting growth hormone, for the treatment of growth hormone deficiency (GHD) in patients weighing at least 25.4 pounds. Skytrofa is Acendis’ first FDA-approved drug, and is also the first once-weekly childhood GHD treatment. Novo Nordisk’s Norditropin is one of the most advantaged GHD therapies, holding preferred status under the pharmacy benefit for 12.8% of all covered lives, and growing to 45.0% with utilization management restrictions applied. Pfizer is also working on a once-weekly childhood GHD drug, with an FDA decision set for October.
SOURCE: MMIT Analytics, as of 8/30/21
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
